in trading halt

In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) request an immediate trading halt in respect of its securities (ASX Code: ANP).
In requesting the trading halt, the Company provides the following information:
• The trading halt is requested pending an announcement on the interim results of ANP’s ATL1103 Phase II clinical trial;
• Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until an announcement is made to the market; and
• The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.